Kyrillos’ appointment goes into effect on June 21, 2024. He joins Tandem with more than 20 years of experience in global executive leadership across medtech, digital health and healthcare management.
Most recently, Kyrillos served in operating company president roles at Envista Holdings from February 2020 to June 2023. His final post there was president of diagnostics and digital solutions. Before that, he served as SVP and GM at Qualcomm Life, the healthcare division of Qualcomm, from May 2016 to February 2019.
Before Qualcomm, Kyrillos served as SVP and GM of infusion solutions at BD for nearly five years. He also held leadership positions at ResMed from 2008 to 2011, culminating in a role as president of ResMed Ventures and Initiatives.
In a news release, Tandem President and CEO John Sheridan said Kyrillos brings “deep experience” in healthcare along with a “great balance” of leadership skills across technical, operational and leadership roles.
“I was drawn to Tandem’s dedication to making a positive impact in the diabetes community, while addressing growing demand for smaller, more advanced insulin delivery technologies,” said Kyrillos. “I look forward to adding my experience to the talented team already in place and helping deliver on Tandem’s mission through the expansion of our global operations while delivering profitable growth.”
